Clinical trials: Endometrial Neoplasms Malignant
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
- Trial name
- NCT06897527
- Testing
- Dostarlimab
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Endometrial Cancer and Endometrial Hyperplasia
the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma
Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital tract in developed countries, while it ranks as the second most frequently occurring neoplasm of women in developing countries, after…
- Trial name
- NCT05619159
- Testing
- microscopic pathological evaluation
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Ovarian Cancer, Endometrial Cancer
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT00315861
- Testing
- pemetrexed, topotecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Adult Fibrosarcoma, Adult Leiomyosarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00659360
- Testing
- saracatinib
- Where
- 4 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy
This study is being done to evaluate the efficacy of robotic approach for staging of endometrial cancer as compared to an equivalent abdominal approach.
- Trial name
- NCT00909896
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Neoplasms, Endometrial
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants.
- Trial name
- NCT07108270
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Endometrial Cancer
ASk Questions in GYnecologic Oncology (ASQ-GYO)
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer
- Trial name
- ASQ-GYO (NCT06339827)
- Testing
- Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ira Winer
Endometrial Cancer
a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer
- Trial name
- SISTER-RAY (NCT06360653)
- Testing
- Stereotactic Post-operative Radiotherapy for Endometrial Cancer
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- ARNAS Civico Di Cristina Benfratelli Hospital
Colorectal Cancer, Endometrial Cancer
Single cEll pRofiling PErsistaNce To ImmuNothErapy
The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer.
- Trial name
- SERPENTINE (NCT06680739)
- Testing
- Durvalumab, Tremelimumab
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Ovarian Cancer
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
An anticipated 200 women with newly diagnosed ovarian and endometrial cancer scheduled to receive chemotherapy (adjuvant chemotherapy after surgery or neoadjuvant chemotherapy before surgery) will be recruited from Smilow Cancer…
- Trial name
- TEAL (NCT05761561)
- Testing
- Exercise and medical nutrition
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Yale University
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
This randomized phase II trial studies how well temsirolimus with or without megestrol acetate and tamoxifen citrate works in treating patients with endometrial cancer that has spread to other places in the body and usually…
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer
- Trial name
- NCT00729586
- Testing
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate
- Where
- 108 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Neoplasms, Endometrial Cancer
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for…
- Conditions
- Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
- Trial name
- PKUPH-ORLPP-EC (NCT07714070)
- Testing
- Orlistat, Progestin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer, Immune Checkpoint Inhibitors
DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER
In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).
- Trial name
- iDEA (NCT07690540)
- Testing
- Prospective exploratory cohort
- Where
- Italy
- Volunteers
- 510 people
- Sponsor
- European Institute of Oncology
Endometrial Carcinosarcoma
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma.
- Trial name
- NCT05156268
- Testing
- Pembrolizumab, Olaparib
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Uterine Cervical Neoplasm, Endometrial Neoplasms
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Online adaptive radiotherapy has demonstrated to be feasible to reduce inter-fractional radiotherapy errors as it re-optimizes treatment plan every fraction.
- Trial name
- NCT05682950
- Testing
- online adaptive radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation…
- Trial name
- NCT05603910
- Testing
- Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Aaron Wolfson
Endometrial Cancer
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
- Trial name
- NCT05761951
- Testing
- DKN-01, Pembrolizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center